Share on StockTwits

InterMune (NASDAQ:ITMN) Director David S. Kabakoff unloaded 5,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $39.56, for a total value of $197,800.00. Following the sale, the director now directly owns 21,600 shares of the company’s stock, valued at approximately $854,496. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of InterMune (NASDAQ:ITMN) traded down 1.31% during mid-day trading on Monday, hitting $39.10. 1,333,822 shares of the company’s stock traded hands. InterMune has a one year low of $9.32 and a one year high of $41.19. The stock has a 50-day moving average of $34. and a 200-day moving average of $23.93. The company’s market cap is $3.866 billion.

InterMune (NASDAQ:ITMN) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter in the previous year, the company posted ($0.64) earnings per share. The company’s revenue for the quarter was up 188.6% on a year-over-year basis. Analysts expect that InterMune will post $-2.34 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at William Blair raised their price target on shares of InterMune from $41.00 to $48.00 in a research note on Thursday, May 22nd. Separately, analysts at ING Group upgraded shares of InterMune from a “market perform” rating to a “buy” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Finally, analysts at Leerink Swann upgraded shares of InterMune from a “market perform” rating to an “outperform” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. InterMune presently has a consensus rating of “Buy” and a consensus price target of $39.08.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.